Abstract
The lateral segment of the globus pallidus (GPl) is thought to be overactive in levodopa-induced dyskinesia in PD. Stimulation of cannabinoid receptors in the GPl reduces gamma-aminobutyric acid (GABA) reuptake and enhances GABA transmission and may thus alleviate dyskinesia. In a randomized, double-blind, placebo-controlled, crossover trial (n = 7), the authors demonstrate that the cannabinoid receptor agonist nabilone significantly reduces levodopa-induced dyskinesia in PD.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Animals
-
Cross-Over Studies
-
Culture Techniques
-
Double-Blind Method
-
Dronabinol / adverse effects
-
Dronabinol / analogs & derivatives*
-
Dronabinol / therapeutic use*
-
Dyskinesia, Drug-Induced / diagnosis
-
Dyskinesia, Drug-Induced / drug therapy*
-
Female
-
Globus Pallidus / drug effects
-
Humans
-
Levodopa / administration & dosage
-
Levodopa / adverse effects*
-
Male
-
Middle Aged
-
Parkinson Disease / diagnosis
-
Parkinson Disease / drug therapy*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Cannabinoid
-
Receptors, Drug / agonists*
-
gamma-Aminobutyric Acid / metabolism
Substances
-
Receptors, Cannabinoid
-
Receptors, Drug
-
nabilone
-
Levodopa
-
gamma-Aminobutyric Acid
-
Dronabinol